BRITISH MEDICAL BULLETIN

VOLUME THIRTY-FOUR
1978

MUCUS

Scientific Editor · · · · · · · · · J R CLAMP

*

THROMBOSIS

Scientific Editor · · · · · · · · DUNCAN THOMAS

*

THE HLA SYSTEM

Scientific Editor · · · · · · · · · W F BODMER

*

Managing Editor · O M HARRISON MBE

MEDICAL DEPARTMENT · THE BRITISH COUNCIL · 65 DAVIES STREET · LONDON · W1Y 2AA

CONTENTS OF VOLUME THIRTY-FOUR

NUMBER 1. *Mucus*

Scientific Editor: J R CLAMP

		PAGE
Introduction	*F Avery Jones*	1
The biochemical and histochemical nomenclature of mucus	*Lynne Reid & J R Clamp*	5
Secretory cells and their glycoproteins in health and disease	*Rosemary Jones & Lynne Reid*	9
Constituents of mucus and their separation	*J M Creeth*	17
Chemical aspects of mucus	*J R Clamp, A Allen, R A Gibbons & G P Roberts*	25
Biosynthesis of mucus glycoprotein	*C F Phelps*	43
Principles of biopolymer gelation: possible models for mucus gel structure	*E R Morris & D A Rees*	49
Is mucus a selective barrier to macromolecules?	*Paul A W Edwards*	55
Control of secretion of tracheobronchial mucus	*J G Widdicombe*	57
Bronchial mucus in health and disease	*Maria Teresa Lopez-Vidriero & Lynne Reid*	63
Meconium in health and disease	*J T Harries*	75
Relation of human gastrointestinal mucus to disease states	*J Schrager & M D G Oates*	79
Functions and physical properties of mucus in the female genital tract	*Max Elstein*	83
Pharmacology of mucus	*D V Parke*	89

Notes on Contributors 95

Book Reviews 97

NUMBER 2. *Thrombosis*

Scientific Editor: DUNCAN THOMAS

		PAGE
Introduction	*Duncan Thomas*	101
Clinical events resulting from thrombus formation	*J R A Mitchell*	103
Surface-mediated reactions in the formation of thrombin, plasmin and kallikrein	*D Ogston & B Bennett*	107
Blood coagulation in pathological thrombus formation and the detection in blood of a thrombotic tendency	*J A Davies & G P McNicol*	113
Contribution of platelets to thrombus formation	*A M White & S Heptinstall*	123
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis	*S Moncada & J R Vane*	129
Thrombosis and atherosclerosis	*Neville Woolf*	137
Antithrombin III and heparin	*T W Barrowcliffe, E A Johnson & Duncan Thomas*	143
Oral contraceptives, blood clotting and thrombosis	*L Poller*	151
Female sex hormones and thrombosis: epidemiological aspects	*M P Vessey & J I Mann*	157
Diagnosis of deep-vein thrombosis	*Norman Browse*	163
Clinical management of venous thromboembolism	*G K Morris & J R A Mitchell*	169
Oral anticoagulants in arterial disease	*M J Mackie & A S Douglas*	177
Platelet suppressive therapy	*A G G Turpie & J Hirsh*	183
Thrombolytic therapy	*V V Kakkar & M F Scully*	191
Thrombus formation and artificial surfaces	*Charles D Forbes & Colin R M Prentice*	201

Notes on Contributors 208

Book Reviews 211

NUMBER 3. *The HLA System*

Scientific Editor: W F BODMER

	PAGE
Introduction — *W F Bodmer*	213
HLA-A, -B and -C antigens, their serology and cross-reaction — *V C Joysey & E Wolf*	217
Cellular typing — *B A Bradley & H Festenstein*	223
Ia antigens: definition of the HLA-DRw specificities — *J G Bodmer*	233
Isolation, structure and genetics of HLA-A, -B, -C and -DRw (Ia) antigens — *C J Barnstable, E A Jones & M J Crumpton*	241
Complement genetics in relation to HLA — *P J Lachmann & M J Hobart*	247
The major histocompatibility system and the immune response — *Alan Munro & Herman Waldmann*	253
Matching for HLA in transplantation — *P J Morris, J R Batchelor & H Festenstein*	259
Transplantation: immunological monitoring — *A Ting, K A Williams & P J Morris*	263
HLA and disease: introductory review — *Heather M Dick*	271
HLA, ankylosing spondylitis and rheumatoid arthritis — *J A Sachs & D A Brewerton*	275
The significance of the association between HLA and multiple sclerosis — *J R Batchelor, Alastair Compston & W I McDonald*	279
HLA genetic heterogeneity in diabetes mellitus — *A G Cudworth & H Festenstein*	285
HLA and coeliac disease — *Pauline Mackintosh & Peter Asquith*	291
HLA and liver disease — *A L W F Eddleston & Roger Williams*	295
The HLA system in acute leukaemia and Hodgkin's disease — *R Harris, Sylvia D Lawler & R T D Oliver*	301
HLA and trophoblastic tumours — *Sylvia D Lawler*	305
Evolution and function of the HLA system — *W F Bodmer & J G Bodmer*	309

Notes on Contributors 317

Book Reviews 321

INDEX TO VOLUME THIRTY-FOUR

Names printed in capitals are those of authors who have contributed papers. Titles of books are printed in italics.

A

Alcoholic liver disease links with HLA, 299
ALLEN A: Structure of gastrointestinal mucus glycoproteins and the viscous and gel-forming properties of mucus, 28
—*see* CLAMP J R, 25
Angina pectoris, oral anticoagulants in, 179
Antibodies, autolymphocytotoxic, 265
Anticoaguiants, administration, effects, 118
—oral, in arterial disease, 177
Antigens, tissue-specific, 264
Antithrombin III, assays, 145
——deficiency, 145
———congenital, 114
——inhibition of clotting factors by, 144
——interaction with thrombin, 144
——purification, 143
Antithrombins, 143
Arachidonic acid, unstable metabolites of, role in haemostasis and thrombosis, 129
Arterial disease, treatment with oral anticoagulants, 177
Arteries, peripheral, disease due to thrombus formation, 105
Arteriovenous shunt thrombosis, platelet suppressive therapy, 187
—shunts, 205
Arthritis, rheumatoid, and HLA, 276
—— HLA association and relative risk, 314
Aspirin, effect on platelet release, 129
ASQUITH P, *see* MACKINTOSH P, 291
Asthma, 98
Atherosclerosis: *The dynamics of atherosclerosis*, 212
—thrombotic complications, 116
Atherosclerotic plaques, platelet antigens in, 138

B

BARNSTABLE C J, JONES E A & CRUMPTON M J: Isolation, structure and genetics of HLA-A, -B, -C and -DRw (Ia) antigens, 241
BARROWCLIFFE T W, JOHNSON E A & THOMAS D: Antithrombin III and heparin, 143
BATCHELOR J R, COMPSTON A & McDONALD W I: The significance of the association between HLA and multiple sclerosis, 279
—*see* MORRIS P J, 259
BENNETT B, *see* OGSTON D, 107
Biographical notes on contributors, 95, 208, 317
Biological standardization: *WHO Expert Committee, Twenty-seventh Report*, 98; *Twenty-eighth Report*, 212
Biopolymer gelation, possible models for mucus gel structure, 49
Blood coagulation changes in venous thrombosis, 115
Blood clotting due to oral contraceptives, 151
——factors, specific assays, 152
———tests for consumption, 119
———thrombogenic effects, 118
——in pathological thrombus formation, 113
——intravascular, disseminated, 116
——proteins, abnormality, 114
——*Recent advances in blood coagulation, Number two*, 211
——surface-mediated, 108, 111
—platelets, adhesion to artificial surfaces, 202
——aggregation, inhibition by arachidonic acid metabolites, 129
——contribution to thrombus formation, 123
——*Platelets in biology and pathology*, 211
——suppressive therapy, 183
—thrombotic tendency, detection, 113, 119
—transfusions, pre-transplant, evaluation, 267
—vessels, prosthetic, 205
BODMER J G: Ia antigens: definition of the HLA-DRw specificities, 233
—*see* BODMER W F, 309
BODMER W F: The HLA system. Introduction to symposium, 213
—Batchelor J R, Bodmer J G, Festenstein H & Morris P J (editors): *Histocompatibility testing 1977: Report of the 7th International Histocompatibility Workshop and Conference*, 324

INDEX TO VOLUME THIRTY-FOUR

BODMER W F & BODMER J G: Evolution and function of the HLA system, 309
Book reviews, 97, 211, 321
BRADLEY B A & FESTENSTEIN H: Cellular typing, 223
BREWERTON D A, *see* SACHS J A, 275
British Pharmacopoeia 1973: Addendum 1977, 98
Bronchial mucus and airway function, 71
——control of secretion, 57
——glycoprotein components, 39
——in health and disease, 63
—secretion and sputum, 63
——rheological properties, 65
BROWSE N: Diagnosis of deep-vein thrombosis, 163
Butterworths medical dictionary, 2nd ed., 323

C

Cardiopulmonary by-pass, 204
Cardiovascular diseases due to oral contraceptives, 151, 157
Catheter, intravenous and intra-arterial, 205
Cell: *Biochemistry of the cell nucleus*, 323
Cellular typing, 223
Cerebral infarction, anticoagulant therapy, 179
Cerebrovascular disease, anticoagulant therapy, 179
——platelet suppressive therapy, 184
Cervix uteri, functions, 84
——mucus, 34
————functions, clinical assessment, 87
————molecular biology, 86
————pharmacology, 91
————physical properties, 84
————ultrastructure, 86
Cheers C, *see* Mandel T E, 322
Ciba Foundation: *Immunology of the gut*, 97
——*Lung liquids*, 98
——*Respiratory tract mucus*, 99
CLAMP J R: Chemical aspects of mucus; general considerations, 25
—ALLEN A, GIBBONS R A & ROBERTS G P: Chemical aspects of mucus, 25
—*see* REID L, 5
Clark T J H & Godfrey S: *Asthma*, 98
Coagulation, *see* Blood coagulation.
Coeliac disease and HLA, 291
——association with B8, 291
——HLA associations and relative risk, 314
Complement genetics in relation to HLA, 247
COMPSTON A, *see* BATCHELOR J R, 279
Contraceptives, oral, and thrombo-embolism, 157
——and venous thrombosis, 115
——blood clotting and thrombosis due to, 151
——stroke due to, 159
Contributors, biographical notes on, 95, 208, 317
Cornea, transplantation, matching for HLA in, 261
Coronary artery disease, oral anticoagulants in, 178
————platelet suppressive therapy, 185
Coumarin, 177
—anticoagulant effects, 118
Council for Postgraduate Medical Education in England and Wales and National Association of Clinical Tutors: *Directory of postgraduate medical centres 1978*, 4th ed., 324
CREETH J M: Constituents of mucus and their separation, 17
Critchley M (editor): *Butterworths medical dictionary*, 2nd ed., 323
CRUMPTON M J, *see* BARNSTABLE C J, 241
CUDWORTH A G & FESTENSTEIN H: HLA genetic heterogeneity in diabetes mellitus, 285
Cystic fibrosis, 76
——diagnosis, 77
——meconium in, 77

D

Dausset J & Svejgaard A (editors): *HLA and disease*, 322
DAVIES J A & McNICOL G P: Blood coagulation in pathological thrombus formation and the detection in blood of a thrombotic tendency, 113
Diabetes mellitus, complications, role of HLA, 289
——HLA and autoimmunity, 288
——HLA and environmental factors, 288
——HLA genetic heterogeneity in, 285
——juvenile-onset, 285
————HLA associations and relative risk, 314
DICK H M: HLA and disease: introductory review, 271
Dictionaries: *Butterworths medical dictionary*, 2nd ed., 323
—*Dictionary of immunology*, 2nd ed., 321
Domenet J G, *see* Mitchell J R A, 211
Doppler flow detector in deep-vein thrombosis, 163
DOUGLAS A S, *see* MACKIE M J, 177
Duguid J B: *Dynamics of atherosclerosis*, 212
Dysfibrinogenaemia, 115

E

EDDLESTON A L W F & WILLIAMS R: HLA and liver disease, 295
Education, medical: *Directory of postgraduate medical centres 1978*, 324
EDWARDS P A W: Is mucus a selective barrier to macromolecules?, 55
ELSTEIN M: Functions and physical properties of mucus in the female genital tract, 83
—& Parke D V (editors): *Mucus in health and disease*, 97
Embolectomy, 173
Embolism, pulmonary, management, 172
——thrombolytic therapy, 195
Extra pharmacopoeia, 27th ed., 99, 100

F

Factor VIII and the endothelial cell, 117
Factor XII, activation, 107
Fatty acids, thrombogenic action, 118
FESTENSTEIN H, *see* BRADLEY B A, 223
—*see* CUDWORTH A G, 285
—*see* MORRIS P J, 259
Fibrin monomer complexes, 113
Fibrinogen uptake test in diagnosis of deep-vein thrombosis, 165
Fibrinolysis, activators, 119
—inhibitors, 118
—surface-mediated, 110
Fibrinopeptide A, 114
Fibrosis, cystic, 76
——diagnosis, 77
——meconium in, 77
Fisher R B: *Joseph Lister 1827–1912*, 324
Fitzgerald factor, 108
Fletcher factor, 108
FORBES C D & PRENTICE C R M: Thrombus formation and artificial surfaces, 201

G

Garland P B & Mathias A P (editors): *Biochemistry of the cell nucleus*, 323
Gastrointestinal tract: *Immunology of the gut*, 97
——mucus, 28
————function, 31
————immunological studies, 81
————pharmacology, 90, 91
————physiology, 31, 79
————relation to disease states, 79
Gene products, tissue distribution recognized by cellular typing, 229
Genetics, complement, in relation to HLA, 247
Genital tract, female, mucus, functions and physical properties, 83
————sources, 83
——mucus, 34
GIBBONS R A: Mucus of the mammalian genital tract, 34
—*see* CLAMP J R, 25
Glycoproteins, bronchial, 67
—from normal and malignant colonic mucosae, 81
————gastrointestinal mucosae, 80
—histochemical identification, 11
—hypersecretion, 13
—intracellular, 11, 13
—of bronchial mucus, 39
—of male genital tract, 34
—of meconium, 76
—of mucus, 5, 18
————biosynthesis, 43
————gelation, 51
—of secretory cells, 9
—synthesis, 13
Godfrey S, *see* Clark T J H, 98
Gordon J L (editor): *Platelets in biology and pathology*, 211
Graves' disease, HLA associations and relative risk, 314

H

Haemochromatosis, HLA association and relative risk, 314, 315
—idiopathic, links with HLA, 295
Haemodialysis, 204
Haemoperfusion, 205
Haemostasis, *see Br. Med. Bull.*, vol. 33, no. 3.
—role of unstable metabolites of arachidonic acid in, 129
Hageman factor, 107
HARRIES J T: Meconium in health and disease, 75
HARRIS R, LAWLER S D & OLIVER R T D: The HLA system in acute leukaemia and Hodgkin's disease, 301
Heart, artificial, 204
—attacks due to thrombus formation, 104
—disease, rheumatic, treatment, 180
—valves, prosthetic, 203
—valvular disease, platelet suppressive therapy, 186
Heparin, 145
—anticoagulant action, 118
—assays, 146
—clinical use, 148
—heterogeneity and fractionation, 147
—mechanism of action, 146
Hepatitis, chronic, active, HLA associations and relative risk, 296, 314
HEPTINSTALL S, *see* WHITE A M, 123
Herbert W J & Wilkinson P C (editors): *A dictionary of immunology*, 2nd ed., 321
HIRSH J, *see* TURPIE A G G, 183
Histocompatibility system and immune response, 253
—testing: *Histocompatibility testing 1977: Report of 7th International Histocompatibility Workshop and Conference*, 324
HLA and ankylosing spondylitis, 271, 275, 314
—and autoimmunity in diabetes mellitus, 288
—and coeliac disease, 291
—and disease, 271
——*HLA and disease*, 322
——associations and linkage disequilibrium, 314
—and environmental factors in diabetes mellitus, 288
—and liver disease, 295
—and multiple sclerosis, 279, 281, 282
—and rheumatoid arthritis, 276, 314
—and trophoblastic tumours, 305
—antigens, alloantigenicity, molecular basis, 245
——amino acid sequence, 245

INDEX TO VOLUME THIRTY-FOUR

——association with β_2 microglobulin, 242
——detection, 219
——genetics, 244
——homozygosity, 219
——inheritance, 218
——matching in transplantation, 262
——molecular size and shape, 244
——orientation within lipid bilayer, 245
——polypeptide composition, 242
——population distribution, 219
——serum procurement and analysis, 221
—complement genetics in relation to, 247
—genetic heterogeneity in diabetes mellitus, 285
—in acute leukaemia, 301
—in Hodgkin's disease, 271, 303
—locus gene frequencies, 309
—matching in transplantation, 259
—specificities, 215
—system, 213–324
——evolution, 309
——genes, duplication, 315
——function, 309
——introduction to symposium, 213
——nomenclature, 215
HLA-A antigens, distribution, 221, 241
——isolation, 241
——serology and cross-reactions, 217
——solubilization, 241
—loci, polymorphism, 309
HLA-B antigens, cellular distribution, 241
——cross-reactions, 218
——distribution, 221
——isolation, 241
——solubilization, 241
—loci, polymorphism, 309
HLA-C antigens, cellular distribution, 241
——cross-reactions, 218
——distribution, 221
——isolation, 241
——solubilization, 241
—loci, polymorphism, 309
HLA-D loci, polymorphism, 309
HLA-DRw antigens, cellular distribution, 241
——isolation, 241
——local equivalents, 238
——solubilization, 241
—locus, 237
——gene frequencies, 309
—specificities, definition, 233
HOBART M J, *see* LACHMANN P J, 247
Hobbs J T (editor): *The treatment of venous disorders*, 212
Hodgkin's disease, HLA system in, 271, 303
Holborow E J & Reeves W G (editors): *Immunology in medicine*, 321
Homocystinuria and thrombo-embolism, 117
Homozygous typing cells, typing techniques, 224
Hosking C S, *see* Mandel T E, 322

I

Ia antigens: definition of HLA-DRw specificities, 233
——identification techniques, 234
——tissue distribution, 234
Immune-response genes associated with major histocompatibility system, 253
Immunoglobulin A, occurrence with mucus, 56
Immunological monitoring in transplantation, 263
Immunology: *Dictionary of immunology*, 2nd ed., 321
—*Essential immunology*, 3rd ed., 321
—*Immunology in clinical medicine*, 3rd ed., 321
—*Immunology in medicine*, 321
—*Immunology of the gut*, 97
—*Progress in immunology III*, 322
—*Recent advances in clinical immunology, Number one*, 321
—*The role of immune complexes in disease: Report of a WHO Scientific Group*, 322
Indanedione, 177
Isotope venography in deep-vein thrombosis, 166

J

JOHNSON E A, *see* BARROWCLIFFE T W, 143
JONES E A, *see* BARNSTABLE C J, 241
JONES F AVERY: Mucus. Introduction to symposium, 1
JONES R & REID L: Secretory cells and their glycoproteins in health and disease, 9
JOYSEY V C & WOLF E: HLA-A, -B and -C antigens, their serology and cross-reaction, 217

K

KAKKAR V V & SCULLY M F: Thrombolytic therapy, 191
Kallikrein formation, surface-mediated reactions in, 107
Kallikrein–kinin system, 108
Kidney transplantation, matching for HLA in, 259
Kininogen, high molecular weight, 108

L

LACHMANN P J & HOBART M J: Complement genetics in relation to HLA, 247
LAWLER S D: HLA and trophoblastic tumours, 305
—*see* HARRIS R, 301
Leukaemia, acute, HLA system in, 301
—lymphoblastic, acute, HLA system in, 301
—myelogenous, acute, HLA system in, 302
Lister: *Joseph Lister 1827–1912*, 324
Literature, medical: *Use of medical literature*, 2nd ed., 323
Liver disease and blood coagulation disturbance, 117
——and HLA, 295
LOPEZ-VIDRIERO M T & REID L: Bronchial mucus in health and disease, 63
Lung clearance and bronchial mucus, 72
—function, relation to sputum volume, 71
—*Lung liquids*, 98
B-lymphocyte antibodies, 265
Lymphocytes, cellular typing, 223

M

McDONALD W I, *see* BATCHELOR J R, 279
McKenzie I F C, *see* Mandel T E, 322
MACKIE M J & DOUGLAS A S: Oral anticoagulants in arterial disease, 177
MACKINTOSH P & ASQUITH P: HLA and coeliac disease, 291
McNICOL G P, *see* DAVIES J A, 113
Major histocompatibility system, 213
————and the immune response, 253
————restrictions on T cells, 255
Mandel T E, Cheers C, Hosking C S, McKenzie I F C & Nossal G J V (editors): *Progress in immunology III*, 322
MANN J I, *see* VESSEY M P, 157
Martindale: *Extra pharmacopoeia*, 27th ed., 99, 100
Mathias A P, *see* Garland P B, 323
Meconium, enzymes, 75
—glycoproteins, 76
—ileus, 77
—in health and disease, 75
—plasma proteins, 75
—sources, 75
β_2 Microglobulin, association with HLA antigens, 242
MITCHELL J R A: Clinical events resulting from thrombus formation, 103
—& Domenet J G (editors): *Thromboembolism: a new approach to therapy*, 211
—*see* MORRIS G K, 169
Mixed lymphocyte culture reaction, inhibition, 233
MONCADA S & VANE J R: Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis, 129
MORRIS E R & REES D A: Principles of biopolymer gelation: possible models for mucus gel structure, 49
MORRIS G K & MITCHELL J R A: Clinical management of venous thrombo-embolism, 169
MORRIS P J, BATCHELOR J R & FESTENSTEIN H: Matching for HLA in transplantation, 259
—*see* TING A, 263
Morton L T (editor): *Use of medical literature*, 2nd ed., 323
Muco-ciliary function, effect of irritants and drugs, 72
Mucus, 1–99
—biochemical nomenclature, 5
—bronchial, and airway function, 71
——control of secretion, 57
——glycoprotein components, 39
——in health and disease, 63
—cervical, 34
——functions, clinical assessment, 87
——molecular biology, 86
——pharmacology, 91
——physical properties, 84
——ultrastructure, 86
—chemistry, 25
—components, separation, 19
—constituents, 17
—gastrointestinal, 28
——function, 31
——immunological studies, 81
——physiology, 31, 79
——relation to disease states, 79
——structure, 28, 31
——pharmacology, 90, 91
—gel structure, models for, 49
—genital tract, 34
————*see also* Cervix uteri; Genital tract, female.
—glycoproteins, 5, 18
——biosynthesis, 43
——components, 17, 19
——gelation, 51
—histochemical aspects, 6
——nomenclature, 6
—introduction to symposium, 1
—*Mucus in health and disease*, 97
—nasal, components, 41
—pharmacology, 59, 89
—protein constituents, 17
—respiratory tract, chemical control of secretion, 59
————chemistry, 39
————control of secretion, 57, 59
————nervous control of secretion, 58
————pharamcology, 89, 91
————*Respiratory tract mucus*, 99
————secretion, immunological reactions, 60
————in pathophysiological conditions, 60
—secretion, effect of drugs, 59, 89
—selective barrier to macromolecules?, 55
—spermatozoa penetration, control, 56
—synthesis rate, effect of drugs, 92
—tracheobronchial, secretion control, 57
Multiple sclerosis and HLA, 272, 279, 281, 282
——HLA association and relative risk, 314
——*see Br. Med. Bull.*, vol. 33, no. 1.
MUNRO A & WALDMANN H: The major histocompatibility system and the immune response, 253
Myasthenia gravis, HLA associations and relative risk, 314
Myocardial infarction, acute, thrombolytic therapy, 195
——due to oral contraceptives, 160
——oral anticoagulants in, 178

N

Neuritis, optic, HLA antigens in, 281
Nossal G J V, *see* Mandel T E, 322
Nunn J F: *Applied respiratory physiology*, 2nd ed., 97

INDEX TO VOLUME THIRTY-FOUR

O

OATES M D G, *see* SCHRAGER J, 79
Oestrogen, thrombogenic actions, 118
Oestrogen-only oral contraceptives, blood clotting due to, 154
OGSTON D & BENNETT B: Surface-mediated reactions in the formation of thrombin, plasmin and kallikrein, 107
Oligosaccharide units of mucus glycoprotein, 39, 45
OLIVER R T D, *see* HARRIS R, 301
Optic neuritis, HLA antigens in, 281

P

PARKE D V: Pharmacology of mucus, 89
—*see* Elstein M, 97
Pharmacopoeias: *British Pharmacopoeia 1973: Addendum 1977*, 98
—*Extra pharmacopoeia*, 27th ed., 99, 100
PHELPS C F: Biosynthesis of mucus glycoprotein, 43
Phlebography in diagnosis of deep-vein thrombosis, 166
Plasmin, 192
—formation, surface-mediated reactions in, 107
Plasminogen, 192
—activators, 191
Platelets, activation tests, 119
—adhesion to artificial surfaces, 202
—aggregation, inhibition by arachidonic acid metabolites, 129
—antigens in atherosclerotic plaques, 138
—contribution to thrombus formation, 123
—interaction with smooth-muscle cells, 141
—*Platelets in biology and pathology*, 211
—suppressive therapy, 183
POLLER L: Oral contraceptives, blood clotting and thrombosis, 151
—(editor): *Recent advances in blood coagulation, Number two*, 211
Postcoital test, 88
Postgraduate medical centres: Directory of, 324
Prekallikrein, 108
PRENTICE C R M, *see* FORBES C D, 201
Progestogen-only oral contraceptives, blood clotting due to, 154
Prostacyclin as vasodilator, 133
—effects on haemostasis and thrombosis, 131
Prostaglandin endoperoxides, 129
Protein core of mucus, 30, 44
Proteoglycans of mucus, 5
Prothrombotic substances, effects of administration, 117
Psoriasis, HLA associations and relative risk, 314

R

REES D A, *see* MORRIS E R, 49
Reeves W G, *see* Holborow E J, 321
REID L & CLAMP J R: The biochemical and histochemical nomenclature of mucus, 5
—*see* JONES R, 9
—*see* LOPEZ-VIDRIERO M T, 63
Reiter's disease, HLA association and relative risk, 314
Respiration: *Applied respiratory physiology*, 2nd ed., 97
—*Lung liquids*, 98
Respiratory tract mucus, chemistry, 39
———control of secretion, 57, 59
———pharmacology, 59, 89, 91
———*Respiratory tract mucus*, 99
Retinal vessels, occlusion, therapy, 196
Reynolds J E F, *see* Wade A, 99
Rheumatic heart disease, anticoagulant therapy, 180
Rheumatoid arthritis and HLA, 276, 314
ROBERTS G P: Chemical aspects of respiratory mucus, 39
—*see* CLAMP J R, 25
Roitt I M: *Essential immunology*, 3rd ed., 321

S

SACHS J A & BREWERTON D A: HLA, ankylosing spondylitis and rheumatoid arthritis, 275
Salivary glands, secretory cells, 9
SCHRAGER J & OATES M D G: Relation of human gastrointestinal mucus to disease states, 79
SCULLY M F, *see* KAKKAR V V, 191
Secretory cells, hyperplasia, 13
———types, 9
Semen, human, 34
Sex hormones, female, and thrombosis, 157
Sims–Hühner test, 88
Snake venoms, thrombogenic action, 118
Sol and gel phases of sputum, 70
Spermatozoa, penetration control by mucus, 56
Spondylitis, ankylosing, and HLA, 271, 275
———HLA association and relative risk, 314
Sputum, bronchial, 63
—chemical constituents, 67
—elasticity, 67
—markers in various diseases, 68
—physical properties, 64
—rheological properties, 65
—viscosity, 66
Streptokinase, dosage and method of administration, 194
—thrombolytic action, 192
Stroke, anticoagulant therapy, 179
—due to oral contraceptives, 159
———thrombus formation, 105
Submucosal glands, structure, 57
Svejgaard A, *see* Dausset J, 322

T

T cells, antigen receptors, biochemical studies on, 258
———cytotoxicity and products of major histocompatibility system, 255
———differentiation, 255
———proliferation, antigen-induced, major histocompatibility system restrictions, 254
Thermography in diagnosis of deep-vein thrombosis, 164
THOMAS D: Thrombosis. Introduction to symposium, 101
—*see* BARROWCLIFFE T W, 143
Thompson R A (editor): *Recent advances in clinical immunology, Number one*, 321
Thrombin activation, tests for, 120
—activity in thrombo-embolic disease, 113
—formation, surface-mediated reactions in, 107
—interaction with antithrombin III, 144
Thrombo-embolism, due to oral contraceptives, 157
—thrombin activity in, 113
—venous, 103
———clinical management, 169
———in pregnancy, management, 174
———platelet suppressive prophylaxis, 187
—*Thromboembolism: a new approach to therapy*, 211
Thrombolysis, mechanism, 192
Thrombosis, 101–212
—and female sex hormones, epidemiological aspects, 157
—arterial, and hypercoagulability, 116
———platelet suppressive therapy, 186
———thrombolytic therapy, 196
—deep-vein, clinical management, 172
———diagnosis, 163
———thrombolytic therapy, 195
—due to oral contraceptives, 151
—introduction to symposium, 101
—mural, experimental, 139
—pathology, 137
—role of unstable metabolites of arachidonic acid in, 129
—substances promoting, 117
—thrombolytic therapy, 191
———clinical studies, 195
———complications, 196
———laboratory control, 194
—venous, and hypercoagulability, 115
———coagulation changes in, 115
Thrombus dissolution, 193
—formation and artificial surfaces, 201
———blood coagulation in, 113
———platelet contribution, 123
———resulting clinical events, 103
TING A, WILLIAMS K A & MORRIS P J: Transplantation: immunological monitoring, 263
Tracheobronchial mucus, control of secretion, 57
Transplantation, immunological monitoring, 263
—matching for HLA in, 259
Tumours, trophoblastic, HLA and, 305
Turk J L: *Immunology in clinical medicine*, 3rd ed., 321
TURPIE A G G & HIRSH J: Platelet suppressive therapy, 183

U

Urokinase, dosage and method of administration, 194

V

VANE J R, *see* MONCADA S, 129
Vasculitis, 117
Veins: *Treatment of venous disorders*, 212
VESSEY M P & MANN J I: Female sex hormones and thrombosis: epidemiological aspects, 157

W

Wade A & Reynolds J E F (editors): *Martindale's extra pharmacopoeia*, 27th ed., 99, 100
WALDMANN H, *see* MUNRO A, 253
Warfarin, 177
WHITE A M & HEPTINSTALL S: Contribution of platelets to thrombus formation, 123
WIDDICOMBE J G: Control of secretion of tracheobronchial mucus, 57
Wilkinson P C, *see* Herbert W J, 321
WILLIAMS K A, *see* TING A, 263
WILLIAMS R, *see* EDDLESTON A L W F, 295
WOLF E, *see* JOYSEY V C, 217
WOOLF N: Thrombosis and atherosclerosis, 137
World Health Organization: *Expert Committee on Biological Standardization:* 27th *Report*, 98; 28th *Report*, 212
———*The role of immune complexes in disease: Report of a WHO Scientific Group*, 322

Printed in Great Britain at The Spottiswoode Ballantyne Press by William Clowes & Sons Limited, London, Colchester and Beccles